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Abstract
Work-related loads, improper lifestyle, increasing obesity, and lack of adequate prophylaxy render low back pain (LBP) one 
of the most common causes of chronic pain worldwide.  
Objective. The aim of the study was to compare the effect of two analgesic drugs on the effectiveness of therapy measured 
by pain intensity. and the degree of disability during treatment of chronic low back pain syndrome  
Material and method. The retrospective analysis involved 185 patients undergoing treatment for chronic low back 
pain syndrome with dexketoprofen (DEX) and diclofenac (DIC). Patients’ gender. place of residence. cause of the pain as 
well as pain intensity in the visual-analogue scale (VAS) and the disability degree (Oswestry Disability Index – ODI) were  
analysed.  
Results. From the first week of treatment to the end of the observation. the DEX group exhibited significantly lower values 
of pain intensity on the disability index. The correlation coefficients between the parameters were significantly higher in 
the DEX group. Analysis of variance demonstrated that the choice of NSAIDs was the most significant factor determining 
the effectiveness of the treatment.  
Discussion. The cause of the pain and place of residence did not have any impact on the treatment efficacy. The 
pharmacological properties of dexketoprofen contribute to its beneficial effect on the therapy used. which validates the 
potential use of DEX in LBP management.  
Summary. The significantly increased correlation between the aforementioned parameters suggests that administration 
of dexketoprofen in the management of non-specific low back pain results in a more rapid return to full physical activity 
and therefore more prompt return to work.
Keywords
low back pain, dexketoprofen, diclofenac, pain treatment, Oswesrty Disability Index
INTRODUCTION
Disorders of the lumbar spine (LBP) are prevalent in all 
western societies [1, 2, 3, 4, 5]. It is extremely disturbing 
that there are increasing numbers of adolescent people with 
such severe symptoms that force doctors to recommend 
hospitalization [6, 7].
Investigations conducted by Kuslich [8] demonstrated that 
the sites responsible for the appearance of pain symptoms 
may equally be the intervertebral discs. facet joints. 
ligaments. fascia. nerve roots and dura structures. When 
these structures are pathological. the syndrome is classified 
as Nonspecific Low Back Pain. in contrast to pain caused by 
nerve root compression called Sciatica.
Work-related loads [9]. improper lifestyle [10]. increasing 
obesity. and lack of adequate prophylaxis contribute to the 
high position of LBP on the list of causes of chronic pain 
worldwide [11] which still remains one of the principal causes 
of public health problems [12].
Non-steroidal anti-inflammatory drugs (NSAID) are the 
most commonly applied medications in LBP management. 
They differ in their chemical composition. anti-inflammatory 
and analgesic potency [13]. and activity against particular 
types of cyclooxygenase [14, 15, 16, 17]. Medical doctors 
usually choose drugs solely on the basis of their knowledge 
of the drug efficacy [18]; therefore. an objective comparative 
research into the use of particular drugs for specific 
indications is valuable [19, 20, 21].
Diclofenac is an aminophenylacetic acid derivative with a 
potent anti-inflammatory. analgesic. and antipyretic activity 
through inhibition of cyclooxygenases. with a considerably 
greater affinity to their constitutive (COX-1) rather induced 
(COX-2) form. Another NSAID is dexketoprofen (propionic 
acid derivative). an S-isomer isolated from a racemic 
ketoprofen mixture. The study carried out by Carabaza 
[22] and Cabre [23] demonstrated that the dextrorotatory 
stereoisomer is a several-fold stronger inhibitor of cyclo-
oxygenase than the non-isolated racemic mixture.
Objective. The aim of the study was to compare the effect of 
two analgesic drugs on therapy efficacy measured by pain 
intensity and the degree of disability during treatment of 
chronic low back pain syndromes. The drugs tested belong to 
different pharmacological groups characterized by a similar 
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MATERIALS AND METHOD
The retrospective analysis involved medical records from 
185 patients of the Outpatient Pain Clinic. Institute of Rural 
Health in Lublin. south-east Poland. treated for chronic pain 
of the lumbosacral spine.
The investigations were carried out in adult patients who 
had previously been treated for non-specific low back pain for 
over two years. and had had six appointments at the clinic on 
a weekly basis. Past operative treatment of the lumbar spine 
or for cancer. and lack of compliance with the weekly visit 
schedule were the criteria for patient exclusion from the study.
Patients receiving dexketoprofen treatment were classified 
into group DEX. and those treated with diclofenac constituted 
group DIC.
Patients’ gender. place of residence. and the cause of the 
pain were analysed. During successive visits scheduled at 
one-week intervals for six weeks. pain intensity was assessed 
in the visual-analogue scale (VAS) and the degree of disability 
estimated using the Oswestry Disability Index (ODI).
Statistical analysis. The differences between the study groups 
were evaluated using a univariate or multivariate analysis of 
variance. taking into account the degrees of freedom (Df). 
the value of Fisher’s test. and statistical significance (p). 
Demographic data (place of residence. gender. and causes of 
pain) were analysed using the non-parametric χ2 test with the χ2 
value. degrees of freedom (Df). and statistical significance (p).
The effect of all the analysed factors (place of residence. 
choice of therapy. choice of NSAID. and duration of therapy) 
on treatment efficacy was assessed by means of a multivariate 
analysis of variance. The correlations between pain intensity 
and degree of disability were analysed using Pearson’s 
coefficient; the equation for the correlation curve is presented 
in the Figures. A p value lower than 0.05 was considered 
statistically significant. Statistic package Statgraphics Plus 
5.1 was used in the analysis.
RESULTS
Among the 185 patients qualified for the analysis. 32 did not 
complete the observation schedule. In all cases of treatment 
intolerance. the drug was replaced by another non-steroidal 
anti-inflammatory drug. Tramadol or low doses of strong 
opioids were administered in the case of inefficacy of the 
treatment, and the data from these patients were subject to 
further analysis (Tab.1).
Table 1. Number of patients in respective groups and patients who did 





Causes of exclusion from the treatment










DEX  90 4 5 4 77
 48.65% 4.44% 5.56% 4.44% 85.56%
DIC  95 5 9 5 76












Abbreviations: DEX – dexketoprofen. DIC – diclofenac
The mean age was 61.36 lat (SD = 13.34; range 25–92). 
Statistical analysis performed with the use of nonparametric 
tests showed that the cause of pain or gender did not have 
a significant impact on the choice of therapy (Tab. 2). Due 
to the large disproportions between the groups. the place of 
residence was not taken into account in further analyses.






Females 60 (77.92%) 52 (69.33%) χ2=2.11; Df=3;  
p = 0.5489Males 17 (22.08%) 23 (30.67%)
Urban 56 (72.73%) 63 (82.89%) χ2=0.83; Df=3;
p = 0.0425Rural 21 (27.27%) 12 (15.79%)
Discopathy 22 (28.57%) 11 (14.47%) χ2 = 0.83; Df=3;  
p=0.425Degenerative changes 55 ()71.43% 64 (84.215%)
DEX – dexketoprofen; DIC – diclofenac; Df – degrees of freedom
The mean values of pain intensity for the respective groups 
during all the examination stages are presented in Table 3 
and Figure 1.
At the first encounter with the patients (stage 0) VAS pain 
intensity scores did not differ between the basic groups (Df=1; 
F = 1.66; p = 0.2009) and reached 6.78 cm (SD = 0.9) for DEX 
and 6.55 cm (SD = 1.03) for DIC.
Table 3. Numerical values of VAS pain intensity and ODI degree of disability 
presented as means and standard deviations in the subsequent test stages
Stages of analyses
0 I II III IV V VI
Groups VAS
DIC 6.78 4.90 3.10 2.90 2.70 2.55 2.61
SD 0.90 1.01 1.01 1.01 1.01 1.07 1.08
DEX 6.55 3.98 2.58 2.20 1.97 1.79 1.78
SD 1.03 0.96 0.88 0.84 0.82 0.89 0.89
Groups ODI
DIC 64.05 53.81 48.39 42.04 35.02 28.63 22.95
SD 10.47 9.90 10.93 11.25 11.32 12.26 12.21
DEX 65.32 48.32 39.39 30.71 24.79 19.54 15.68
SD 10.56 9.67 10.60 9.94 9.70 10.44 11.51
DIC – diclofenac; DEX – dexketoprofen; SD – standard deviation

















Stages of the observations
Figure 1. VAS pain intensity. Comparison of mean values in groups of patients 
treated with dexketoprofen (DEX) and diclofenac (DIC) during the consecutive 
stages of the observations
* p<0.05
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After the first week of treatment (Stage 1), the pain intensity 
value decreased in all the patients, reaching 3.98 (SD = 0.95) 
for DEX and 4.90 for DIC (SD = 1.01). Significant differences 
between the test groups (Df=1; F = 24.06; p = 0.0001), which 
persisted throughout the observation, were demonstrated by a 
univariate analysis of variance, as in the case of the disability 
index (ODI) values. The values did not differ between the 
patient groups in the initial stage of the observation (Df=1; 
F = 45.44; p=0.5264) and decreased significantly from the 
first treatment stage reaching 53.81 (DS. = 9.90), for the 
DIC group and 48.32 (SD = 9.67) for the DEX group. In this 
stage, statistical significance of the differences between the 
described values was found (Df = 1; F = 8.72; p = 0.004). which 
persisted until the end of the observation. The numerical data 
concerning the degree of disability are presented in Table 3; 
Figure 2 presents the graphic illustration.
Figure 2. Degree of disability measured by Oswestry Disability Index (ODI). 
Comparison of mean values in patient groups treated with dexketoprofen (DEX) 
and diclofenac (DIC) during successive stages of observation
* – p<0.001
Analysis of the correlation between pain intensity (VAS) 
and degree of disability was performed and demonstrated 
a higher correlation between these two parameters in the 
group of patients receiving dexketoprofen (Fig. 3 and 4). 
The multivariate analysis of variance demonstrated that the 
choice of the NSAID had the most significant impact on 
treatment efficacy (Tab. 4)
Figure 3. Graph of the curve of correlation between degree of disability measured 
by Oswestry Disability Index (ODI) and pain intensity in the VAS in all patients 
treated with dexketoprofen DEX. Correlation coefficient 0.755. The equation for 
the curve is given in the upper right corner
Figure 4. Graph of the curve of correlation between degree of disability measured 
by Oswestry Disability Index (ODI) and pain intensity in the VAS in all patients 
treated with diclofenac DIC. Correlation coefficient 0.549. The equation for the 
curve is given in the upper right corner.









Choice of NSAID Df=1  F=18.73 p<0.0000
Cause of pain Df=1 F=0.06 p=0.8011
Place of residence Df=1 F= 1.50 p=0.2227
Gender Df=1 F= 0.05 p=0.8323
DISCUSSION
Attempts to develop the most effective therapy for non-
specific low back pain are continuously being undertaken. 
Treatment should prevent occurrence of chronic pain 
[24]. and allow a prompt return to work. Appropriate pain 
control and restoration of physical activity are regarded by 
the authors as key factors for guidelines based on a meta-
analysis of research papers [25, 26].
Lumbar pain constitutes a serious medical problem due 
to its high prevalence and disabilities accompanying this 
disease, which is reflected in the general condition of public 
health [27]. The study conducted by Fredheim et  al. [28] 
showed a significantly poorer quality of life in patients 
whose disability was not associated with cancer disease. 
The condition analysed in the presented study should also 
be considered from the socio-economic aspect, since the 
costs of treatment are extremely high. Research carried out 
in the Swedish population also demonstrated that the direct 
costs are very high (3,100 euros per year), but the indirect 
costs are substantially greater and reach as much as 17,600 
euros [29]. Therefore, it is crucial that the treatment methods 
employed ensure the regaining of full physical activity and 
prompt return to work.
A majority of the patients presented in the paper exhibited 
a substantial degree of disability confirmed by the ODI. The 
study has shown that application of dexketoprofen resulted in 
significantly more rapid reduction in both pain intensity and 
the degree of disability. Since the study was not randomized, 
the results obtained allow only a reasonable assumption that 
the tested drug will facilitate faster and complete recovery.
In terms of pathophysiology, in both groups, pain was 
classified as receptor pain, i.e. pain that can be effectively 
treated according to the ‘WHO analgesic ladder’ scheme 
[30, 31, 32].
















































Stages of the observations
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In the available literature, low back pain is classified into 
specific pain (related to pressure exerted of pathological 
structures on the nerve root) and non-specific (connected 
with pathology of the motion segment) [25, 26, 33, 34, 35]. 
No classification has been reported that would differentiate 
the non-specific low back pain depending on the immediate 
cause of pain. Therefore, the material described here is in 
accordance with literature data, as no distinct differences 
were found between the decrease in pain intensity in the 
case of a degenerative spine disease and discopathy in the 
lumbar segment. Similar efficacy was demonstrated in pain 
treatment in both discopathy and degenerative changes in the 
lumbosacral spine segment. This corroborated the thesis that 
the choice of an appropriate NSAID is the most important 
factor in rapid recovery.
The investigations conducted by Ekman et  al. showed 
that the female gender is one of the important factors 
inducing the development of chronic pain [23]. The results 
of the retrospective study, as well as examinations of adult 
populations in Hong Kong, Norway, and Brazil [36, 37, 
38] fully confirmed these data. However, no impact of 
patients’ gender on the course of administered treatment 
or its effectiveness assessed after a six-week period was 
demonstrated. This indicates that treatment methods 
should be selected exclusively on the basis of the pain 
pathomechanism [30, 39,40, 41].
Drugs containing a dextrorotatory ketoprofen isomer 
exhibit a more potent analgesic and anti-inflammatory 
activity [42, 43]. Potentiation of the analgesic action of opioids 
upon administration of even sub-analgesic dexketoprofen 
doses has been reported from animal experiments [44]; 
furthermore, the drug has been found to be effective in 
bone metastases [45]. Additionally, it has been reported that 
the drug tested had a significant effect on inhibition of the 
wind-up phenomenon, one of the causes of chronic pain 
development [46]. It cannot be excluded that this mechanism 
may play a substantial role and be the cause of the significantly 
higher correlation between the changes in pain intensity and 
the degree of disability in patients treated with DEX.
Dexketoprofen was shown to have strong analgesic activity, 
both in the initial stage of the disease and later when the issue 
of long-term therapy efficacy, is of the greatest importance, 
which has been confirmed by a meta-analysis of 45 papers 
concerning acute and chronic pain [47].
Not only the differences between the patient groups treated 
with the different anti-inflammatory drugs, but also the 
dynamics of pain intensity changes were significant, as 
diclofenac in the daily dose of 100 milligrams reached the 
maximum effect in the third week of the treatment. This is 
apparently contradictory to the work of Zippel et al. [48]. who 
did not find differences in pain intensity in patients receiving 
diclofenac or dexketoprofen as a low back pain therapy. 
However, the presented results should not be compared, 
as the publication cited described treatment of acute pain, 
both drugs were administered via intramuscular injections, 
and the data analysed referred to the period immediately 
after drug administration. The problem requires further 
investigations with the use of a double-blind test.
CONCLUSIONS
Comparison of the two non-steroidal anti-inflammatory 
drugs demonstrated the higher efficacy of dexketoprofen 
in all the treatment stages; it exerted an effect on both pain 
intensity and the degree of disability. The significantly 
increased correlation between the two parameters suggests 
that the administration of dexketoprofen in the management 
of non-specific low back pain results in rapid restoration of 
full physical activity, and therefore a more prompt return 
to work.
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